The partners will co-create a novel target identification platform that leverages Aignostics’ technology and proprietary multimodal patient cohorts, and Bayer’s deep expertise in discovering and developing novel oncology therapies. In addition, the collaboration will include the development of computational pathology algorithms powered by AI and machine learning (ML) that connect baseline pathology data, such as molecular tumor profiles, with clinical data, such as patient outcomes, to enable better patient identification, stratification, and selection for clinical trials.
Bayer, Aignostics to collaborate on next generation precision oncology
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-03-17 04:30 GMT | Update On 2024-03-19 11:41 GMT
Advertisement
Berlin: Bayer and Aignostics GmbH have announced a strategic collaboration on several artificial intelligence (AI)-powered approaches with applications in precision oncology drug research and development. Aignostics is a spin-off from one of the world’s leading hospitals, Charité-Universitätsmedizin Berlin.
"Gaining insights into human disease biology, discovering targets with a strong disease link by integrating artificial intelligence, machine learning and multimodal pathology into precision drug development has a huge potential for our R&D innovation strategy. Bringing Aignostics' technical knowhow and their access to large patient datasets together with Bayer's expertise in cancer research and development will enable discoveries and faster clinical development, helping to provide cancer patients with more impactful medicines," Christian Rommel, Member of the Executive Committee of Bayer’s Pharmaceuticals Division and Head of Research and Development said.
The collaboration will leverage Aignostics’ technology and access to longitudinal, multimodal clinical data sets in well characterized patient cohorts to discover new oncology targets for high unmet medical need indications. Under the terms of the agreement, the companies will collaborate on multiple discovery programs and initiate at least two target identification programs.
“Innovation at Aignostics has always been fueled by close collaboration with clinicians and biopharma. With this partnership, we’re thrilled to take that approach to the next level. Fusing our technology and multimodal data with Bayer’s extensive expertise in drug discovery and clinical development has the potential to generate better drugs for patients with high unmet need in less time. Together with Bayer, we’re excited to transform AI’s immense potential into a reality for healthcare,” said Viktor Matyas, CEO of Aignostics GmbH.
Aignostics will receive an upfront payment and is eligible to receive success-based milestone payments and royalties on any commercialized therapies that result from the collaboration.
Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading VC investors and has operations in Berlin and New York.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.